Aug 6, 2026 06:58AM
Jul 1, 2026 07:03AM
Apr 6, 2026 06:53AM
Dec 2, 2025 06:43AM
Aug 28, 2025 08:00AM
Jul 8, 2025 08:00AM
Jun 4, 2025 06:15AM H.C. Wainwright Assumes Akebia Therapeutics (AKBA) at Buy
May 13, 2025 08:00AM
Apr 4, 2025 06:42AM
Mar 19, 2025 10:17PM
Mar 17, 2025 06:42AM
Jan 24, 2025 06:41AM
Jan 15, 2025 06:41AM
Jan 14, 2025 11:06AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)
Oct 11, 2024 06:37AM
Oct 8, 2024 06:49AM
Sep 6, 2024 06:55AM
Aug 26, 2024 08:00AM
Aug 12, 2024 06:13AM
Jun 27, 2024 08:18AM
Apr 1, 2024 11:09AM Akebia Therapeutics (AKBA) PT Raised to $6 at H.C. Wainwright, 'favorable label to daprodustat'
Sep 6, 2023 08:00AM
Aug 28, 2023 06:08AM
Jul 19, 2023 07:45AM
Sep 1, 2022 08:30AM
Jul 1, 2022 06:07AM
May 19, 2022 08:30AM
Apr 8, 2022 06:11AM H.C. Wainwright Reiterates Neutral Rating, $2 PT on Akebia Therapeutics (AKBA)
Mar 31, 2022 07:11AM
Feb 23, 2022 10:35AM
Jan 10, 2022 06:00AM
Sep 1, 2021 08:00AM
Mar 2, 2021 08:00AM
Jan 6, 2021 08:00AM
Sep 8, 2020 08:00AM Akebia Therapeutics Announces September 2020 Investor Conference Schedule
May 19, 2020 04:05PM
May 12, 2020 05:50AM
May 11, 2020 09:15PM
May 11, 2020 04:02PM
May 11, 2020 04:01PM
Aug 6, 2019 07:14AM
Jul 11, 2019 07:16AM Akebia Therapeutics (AKBA) PT Lowered to $21 at H.C. Wainwright
Apr 3, 2019 08:45AM
Nov 13, 2018 04:05PM
Aug 30, 2018 04:05PM
Jun 6, 2018 07:12AM
Mar 21, 2018 08:30AM
Jul 10, 2017 07:49AM
Jul 6, 2017 07:00AM Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
Jun 29, 2017 05:37AM

21,837 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All